CN118290332A - Preparation method of polyphenol compound - Google Patents
Preparation method of polyphenol compound Download PDFInfo
- Publication number
- CN118290332A CN118290332A CN202410392995.4A CN202410392995A CN118290332A CN 118290332 A CN118290332 A CN 118290332A CN 202410392995 A CN202410392995 A CN 202410392995A CN 118290332 A CN118290332 A CN 118290332A
- Authority
- CN
- China
- Prior art keywords
- reaction
- intermediate product
- compound
- organic solvent
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 polyphenol compound Chemical class 0.000 title claims abstract description 28
- 235000013824 polyphenols Nutrition 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 238000006243 chemical reaction Methods 0.000 claims abstract description 69
- 239000013067 intermediate product Substances 0.000 claims abstract description 41
- 239000002994 raw material Substances 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 16
- 150000001875 compounds Chemical class 0.000 claims abstract description 10
- 238000006467 substitution reaction Methods 0.000 claims abstract description 10
- 229940126062 Compound A Drugs 0.000 claims abstract description 9
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims abstract description 9
- 238000005660 chlorination reaction Methods 0.000 claims abstract description 9
- 125000002252 acyl group Chemical group 0.000 claims abstract description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 6
- 239000001257 hydrogen Substances 0.000 claims abstract description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 54
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 37
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 24
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 18
- 239000003960 organic solvent Substances 0.000 claims description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 14
- 239000003054 catalyst Substances 0.000 claims description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- 239000012295 chemical reaction liquid Substances 0.000 claims description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 12
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims description 10
- 150000007529 inorganic bases Chemical class 0.000 claims description 10
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 claims description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 8
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical group COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- JIKUXBYRTXDNIY-UHFFFAOYSA-N n-methyl-n-phenylformamide Chemical compound O=CN(C)C1=CC=CC=C1 JIKUXBYRTXDNIY-UHFFFAOYSA-N 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 7
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 claims description 6
- HEQOJEGTZCTHCF-UHFFFAOYSA-N 2-amino-1-phenylethanone Chemical compound NCC(=O)C1=CC=CC=C1 HEQOJEGTZCTHCF-UHFFFAOYSA-N 0.000 claims description 5
- GLDQAMYCGOIJDV-UHFFFAOYSA-N 2,3-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC(O)=C1O GLDQAMYCGOIJDV-UHFFFAOYSA-N 0.000 claims description 4
- IBHWREHFNDMRPR-UHFFFAOYSA-N 2,4,6-Trihydroxybenzoic acid Chemical compound OC(=O)C1=C(O)C=C(O)C=C1O IBHWREHFNDMRPR-UHFFFAOYSA-N 0.000 claims description 4
- UIAFKZKHHVMJGS-UHFFFAOYSA-N 2,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1O UIAFKZKHHVMJGS-UHFFFAOYSA-N 0.000 claims description 4
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 claims description 4
- AKEUNCKRJATALU-UHFFFAOYSA-N 2,6-dihydroxybenzoic acid Chemical compound OC(=O)C1=C(O)C=CC=C1O AKEUNCKRJATALU-UHFFFAOYSA-N 0.000 claims description 4
- UYEMGAFJOZZIFP-UHFFFAOYSA-N 3,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC(O)=C1 UYEMGAFJOZZIFP-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- BRTFVKHPEHKBQF-UHFFFAOYSA-N bromocyclopentane Chemical compound BrC1CCCC1 BRTFVKHPEHKBQF-UHFFFAOYSA-N 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 229940082044 2,3-dihydroxybenzoic acid Drugs 0.000 claims description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 2
- 150000001263 acyl chlorides Chemical class 0.000 claims description 2
- 229940114055 beta-resorcylic acid Drugs 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 239000012312 sodium hydride Substances 0.000 claims description 2
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 2
- 239000000047 product Substances 0.000 abstract description 8
- 238000003786 synthesis reaction Methods 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 5
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract description 3
- 230000003197 catalytic effect Effects 0.000 abstract description 3
- 230000026030 halogenation Effects 0.000 abstract description 2
- 238000005658 halogenation reaction Methods 0.000 abstract description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract description 2
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 2
- 238000007363 ring formation reaction Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 20
- 238000004809 thin layer chromatography Methods 0.000 description 13
- 239000007787 solid Substances 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- 238000001035 drying Methods 0.000 description 8
- 238000012544 monitoring process Methods 0.000 description 8
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical group ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- VFRLJCKMHUJGFR-UHFFFAOYSA-N 5,7,8-trimethoxy-2-phenylchromen-4-one Chemical compound COC=1C(OC)=CC(OC)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 VFRLJCKMHUJGFR-UHFFFAOYSA-N 0.000 description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
- 230000000324 neuroprotective effect Effects 0.000 description 5
- URSUMOWUGDXZHU-UHFFFAOYSA-N 4',5,6,7-tetramethoxyflavone Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C=C2O1 URSUMOWUGDXZHU-UHFFFAOYSA-N 0.000 description 4
- CGTZOVPQCMHAIE-UHFFFAOYSA-N 5,8-dihydroxy-7-methoxy-2-phenylchromen-4-one Chemical compound OC=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 CGTZOVPQCMHAIE-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- DJSISFGPUUYILV-UHFFFAOYSA-N UNPD161792 Natural products O1C(C(O)=O)C(O)C(O)C(O)C1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-UHFFFAOYSA-N 0.000 description 4
- NPLTVGMLNDMOQE-UHFFFAOYSA-N carthamidin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=C(O)C(O)=C2C(=O)C1 NPLTVGMLNDMOQE-UHFFFAOYSA-N 0.000 description 4
- OMHNVUCFPJJLKD-UHFFFAOYSA-N chembl1951865 Chemical compound C1=C(O)C(O)=CC=C1C1=CC(OC2CCCC2)=C(C=CC=C2)C2=N1 OMHNVUCFPJJLKD-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- ZFKKRRMUPBBYRS-UHFFFAOYSA-N norwogonin Chemical compound OC=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 ZFKKRRMUPBBYRS-UHFFFAOYSA-N 0.000 description 4
- DJSISFGPUUYILV-ZFORQUDYSA-N scutellarin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-ZFORQUDYSA-N 0.000 description 4
- 229930190376 scutellarin Natural products 0.000 description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 2
- VTCDZPUMZAZMSB-UHFFFAOYSA-N 3,4,5-trimethoxyphenol Chemical compound COC1=CC(O)=CC(OC)=C1OC VTCDZPUMZAZMSB-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- XHEFDIBZLJXQHF-UHFFFAOYSA-N fisetin Chemical compound C=1C(O)=CC=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 XHEFDIBZLJXQHF-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000010413 mother solution Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
- BYOKJLCIKSFPDU-UHFFFAOYSA-N 3,4-bis(phenylmethoxy)benzoic acid Chemical compound C=1C=CC=CC=1COC1=CC(C(=O)O)=CC=C1OCC1=CC=CC=C1 BYOKJLCIKSFPDU-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- ARANIYZUAHNSJX-UHFFFAOYSA-N 8-bromo-5,7-dimethoxy-2-phenylchromen-4-one Chemical compound BrC=1C(=CC(=C2C(C=C(OC=12)C1=CC=CC=C1)=O)OC)OC ARANIYZUAHNSJX-UHFFFAOYSA-N 0.000 description 1
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- VHLJDTBGULNCGF-UHFFFAOYSA-N Limonin Natural products CC1(C)OC2CC(=O)OCC23C4CCC5(C)C(CC(=O)C6OC56C4(C)C(=O)CC13)c7cocc7 VHLJDTBGULNCGF-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- MXMOTZIXVICDSD-UHFFFAOYSA-N anisoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1 MXMOTZIXVICDSD-UHFFFAOYSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 description 1
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 1
- 229940015301 baicalein Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical group ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- KRAHENMBSVAAHD-UHFFFAOYSA-N ethyl 3-(4-methoxyphenyl)-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)C1=CC=C(OC)C=C1 KRAHENMBSVAAHD-UHFFFAOYSA-N 0.000 description 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000011990 fisetin Nutrition 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- KBDSLGBFQAGHBE-MSGMIQHVSA-N limonin Chemical compound C=1([C@H]2[C@]3(C)CC[C@H]4[C@@]([C@@]53O[C@@H]5C(=O)O2)(C)C(=O)C[C@@H]2[C@]34COC(=O)C[C@@H]3OC2(C)C)C=COC=1 KBDSLGBFQAGHBE-MSGMIQHVSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
Abstract
The invention belongs to the technical field of compound synthesis and preparation, and provides a preparation method of a polyphenol compound. The method takes a compound A as a raw material, firstly carries out benzyloxy substitution to protect hydroxyl, then carries out acyl chlorination, acetyl phenyl substitution and cyclization reaction in sequence to obtain an intermediate product M3, and finally removes benzyloxy through hydroxyl halogenation and catalytic hydrogen substitution to obtain a target product polyphenol compound B. The invention provides a new synthetic route of polyphenol compounds, which has the advantages of green and safe raw materials, simple reaction conditions, high yield and high purity of target products, and can be used for large-scale production.
Description
Technical Field
The invention belongs to the technical field of compound synthesis and preparation, and relates to a preparation method of a polyphenol compound.
Background
Neurodegenerative disorders such as diabetes, parkinson's disease, huntington's chorea, alzheimer's disease, non-Alzheimer's dementia, multiple sclerosis, traumatic brain injury, spinal cord injury or ALS, etc., have a great influence on the quality of life of the patient. Existing treatment methods have certain limitations, and there is an urgent need to find novel drugs with multiple neuroprotective properties.
Chinese patent application CN103929959a discloses a neuroprotective polyphenol analogue (shown as formula i), a synthetic analogue of certain polyphenols such as feissones, baicalein or chlorogenic acid, having neuroprotective, anti-inflammatory, glutathione-promoting and/or antioxidant properties, useful for promoting, enhancing and/or increasing the protection, growth and/or regeneration of neurons.
The polyphenol compound can be obtained by extracting and separating natural plants containing the polyphenol compound as raw materials, but the extraction process has higher requirements on experimental conditions and instruments, lower yield, multiple types of extracts and complex post-separation treatment. The chemical synthesis can obtain the target compound through reasonable synthesis route design, has the characteristics of simple process, high yield and less byproducts, and is to be researched in the preparation of the neuroprotective polyphenol compound.
The Chinese patent application CN109020940A discloses a method for synthesizing scutellarin, which comprises the following steps: step 1) synthesizing ethyl p-methoxybenzoyl acetate by adopting ethyl acetoacetate and p-methoxybenzoyl chloride as raw materials; step 2) synthesizing p-methoxybenzoyl ethyl acetate and 3,4, 5-trimethoxyphenol to obtain 5,6,7,4' -tetramethoxy flavone; step 3) removing methyl from 5,6,7,4' -tetramethoxyflavone to obtain crude scutellarin, and purifying the crude scutellarin to obtain high-content refined scutellarin (shown in formula II). Although the method solves the problems of low yield and dangerous reagent use in the prior art, the reaction process requires high pressure conditions and the reaction conditions are harsh.
Chinese patent CN104926768B discloses a synthesis method of threo limonin, iso-wogonin and norwogonin, comprising the following steps, (1) reacting 5, 7-dimethoxy-8-bromo-flavone with sodium methoxide under the catalysis of cuprous salt to generate 5,7, 8-trimethoxyflavone; (2) Under the action of aluminum trichloride, 5,7, 8-trimethoxy flavone reacts in inert atmosphere to obtain the threo-limonin. On the basis of the method, su Jizhu Huang Tongtuo methyl groups can be further processed to respectively obtain the iso-wogonin and the norwogonin (the structure is shown as a formula III). The method has the advantages of wide raw material sources, good selectivity and mild conditions, but the yield is still lower, and the maximum is only 60%.
PAMELA MAHER ET AL in "Chemical Modification of the Multitarget Neuroprotective Compound Fisetin"(J.Med.Chem.2012,55,378-389), discloses the synthesis of quinoline derivatives (see formula IV) by condensing 2' -amino-paracetamol with an appropriately substituted aldehyde using sulfuric acid in methanol with a final yield of 15-40%.
In general, the existing synthesis methods mainly have the problems of environmental pollution of raw materials, harsh reaction conditions, and particularly low yield of target products, thereby limiting the wide application of the compounds.
Disclosure of Invention
Aiming at the problems existing in the prior art, the invention provides a preparation method of a polyphenol compound, which takes a compound A as a raw material, firstly carries out benzyl substitution to protect hydroxyl, then carries out acyl chlorination, acetyl phenyl substitution and cyclization reaction in sequence to obtain an intermediate product M3, and finally carries out hydroxyl halogenation and catalytic hydrogen substitution to obtain a target product polyphenol compound B. The route has the advantages of green and safe raw materials, simple reaction conditions, ideal target product yield and high purity, and can be used for large-scale production.
The invention provides a preparation method of polyphenol compounds, the synthetic route is as follows:
Wherein R 1 represents 2-3-OH groups, R 2 represents the same-OCH 2 Ph groups as the-OH substitution positions and the same number in R 1;
the method specifically comprises the following steps:
Step I: adding a raw material compound A, benzyl bromide and inorganic base into an organic solvent A, heating for reaction, cooling to room temperature after the reaction is finished, filtering, adding alkali metal hydroxide, stirring for reaction, and obtaining an intermediate product M1;
Step II: taking an intermediate product M1 for acyl chlorination reaction, removing a solvent after the acyl chlorination reaction is finished, and dissolving the solvent in dichloromethane to obtain a reaction liquid 1; dissolving 2-aminoacetophenone in an organic solvent B, and adding triethylamine to obtain a reaction solution 2; dropwise adding the reaction liquid 2 into the reaction liquid 1, and stirring for reaction to obtain an intermediate product M2;
step III: mixing an intermediate product M2, 1, 4-dioxane and alkali metal hydroxide, and heating to react to obtain an intermediate product M3;
Step IV: adding an intermediate product M3, bromocyclopentane and inorganic base into an organic solvent C, and stirring for reaction to obtain an intermediate product M4;
step V: and adding the intermediate product M4 and the palladium-carbon catalyst into the organic solvent D, and introducing hydrogen for replacement to obtain the polyphenol compound.
Further, the compound A is selected from 2, 3-dihydroxybenzoic acid, 2, 4-dihydroxybenzoic acid, 2, 5-dihydroxybenzoic acid, 2, 6-dihydroxybenzoic acid, 3, 4-dihydroxybenzoic acid, 3, 5-dihydroxybenzoic acid, 3,4, 5-trihydroxybenzoic acid or 2,4, 6-trihydroxybenzoic acid; the benzyl halide is selected from benzyl chloride or benzyl bromide.
Further, in step I and step IV, the inorganic base is independently selected from potassium carbonate, sodium carbonate and/or sodium hydride; in step I and step III, the alkali metal hydroxide is selected from sodium hydroxide, potassium hydroxide and/or lithium hydroxide.
Further, in the step II, the acyl chlorination reaction process is as follows: firstly, adding dichloromethane into the intermediate product M1, then adding N, N-dimethylformamide or N-methyl-N-phenylformamide, and dripping an acyl chloride reagent for reaction.
Still further, the intermediate M1, the acid chlorinating agent, methylene chloride and N, N-dimethylformamide or N-methyl-N-phenylformamide were used in a ratio of 1g:0.5-50mol:1-100mL:0.5-50mL.
In some embodiments of the invention, the acid chloride reagent is selected from oxalyl chloride, thionyl chloride, or phosphorus oxychloride.
Further, the acid chlorination reaction is carried out at 20 to 30 ℃.
Further, the organic solvent a is selected from N, N-dimethylformamide or N-methyl-N-phenylformamide; the organic solvent B is selected from acetonitrile, dichloromethane, ethylene glycol dimethyl ether, methanol or acetone; the organic solvent C is selected from N, N-dimethylformamide or N-methyl-N-phenylformamide; the organic solvent D is at least one selected from acetonitrile, dichloromethane, ethylene glycol dimethyl ether and methanol.
Further, in the step I, the dosage ratio of the compound A, benzyl bromide and inorganic base is 1mol:0.35-35mol:0.5-50mol; the molar ratio of the compound A to the alkali metal hydroxide is 1:0.2-20.
Further, in the step II, the dosage mole ratio of the intermediate product M1, triethylamine and 2-aminoacetophenone is 1mol:0.5-50mol:0.105-10.5mol.
Further, in the step III, the ratio of the amount of the intermediate M2, 1, 4-dioxane and the alkali metal hydroxide is 1mol:1-100mL:0.25-25mol.
Further, in the step IV, the dosage ratio of the intermediate product M3, the bromocyclopentane and the inorganic base is 1mol:0.1-10mol:0.2-20mol.
Further, in the step V, the mass ratio of Pd to C in the palladium-carbon catalyst is 0.03-0.3:1, a step of; the palladium carbon catalyst is used in an amount of 8 to 12wt% of the intermediate product M4.
Preferably, in the step v, the mass ratio of Pd to C in the palladium-carbon catalyst is 0.1:1, a step of; the palladium on carbon catalyst was used in an amount of 10wt% of the intermediate product M4.
Further, in the step I, the heating reaction temperature is 0-80 ℃.
Further, in the step II, the stirring reaction is carried out at 0-20 ℃.
Further, in the step III, the temperature is 50-100 ℃.
Further, in the step IV, the stirring reaction temperature is 50-100 ℃.
Compared with the prior art, the invention has the following beneficial effects:
(1) The invention takes polyhydroxy compound as raw material, protects hydroxyl by benzyloxy substitution, and finally obtains polyphenol compound by catalytic hydrogen replacement after series reaction; compared with the traditional preparation process, the preparation method has the advantages of green and pollution-free;
(2) The synthetic route of the invention does not relate to the reaction process with harsh conditions, has simple operation and high efficiency, can realize purification treatment by recrystallization, and does not need operations such as column chromatography and the like; meanwhile, the yield of each reaction step reaches more than 90% on the premise of ensuring the purity of the product by optimizing the dosage proportion of reactants and the reaction temperature in each reaction process, so that the yield of the overall reaction is improved;
(3) The method has simple integral route and easy operation, and is suitable for industrialized amplified production.
Drawings
FIG. 1 is a synthetic route diagram of the polyphenol compound of the present invention;
FIG. 2 is a nuclear magnetic H-profile of intermediate M3 (N- (2-acetylphenyl) -3, 4-bis (benzyloxy) benzamide) prepared according to example 3 of the invention;
FIG. 3 is a nuclear magnetic H-pattern of intermediate M4 (2- [3, 4-bis (benzyloxy) phenyl ] quinolin-4-ol) prepared according to example 4 of the invention;
FIG. 4 is a nuclear magnetic resonance H-spectrum of a target product compound B (4- (4- (cyclopentyloxy) quinolin-2-yl) benzene-1, 2-diol) prepared in example 5 of the present invention.
Detailed Description
The following non-limiting examples will enable those of ordinary skill in the art to more fully understand the invention and are not intended to limit the invention in any way. The following is merely exemplary of the scope of the invention as claimed and many variations and modifications of the invention will be apparent to those skilled in the art in light of the disclosure, which are intended to be within the scope of the invention as claimed.
The synthetic route of the polyphenol compound of the present invention is shown in FIG. 1.
The preparation method of the present invention will be described in detail by taking the synthesis of polyphenol compound 4- (4- (cyclopentyloxy) quinolin-2-yl) benzene-1, 2-diol as an example.
Example 1
The intermediate M1 (3, 4-bis (benzyloxy) benzoic acid) was prepared as follows:
(1) 25g (0.162 mol) of raw material 3, 4-dihydroxybenzoic acid is taken and added into 250mL of N, N-dimethylformamide, 112g (0.81 mol) of potassium carbonate and 97g (0.567 mol) of benzyl bromide are added, the temperature is raised to 40 ℃, the mixture is stirred for 2 hours, and the reaction is stopped after the thin layer chromatography monitors that the raw material is reacted;
(2) Cooling the reaction solution to room temperature, filtering to remove potassium carbonate, adding 13g (0.324 mol) of sodium hydroxide into the mother solution, stirring for 1h at room temperature, monitoring the reaction completely by using thin layer chromatography, and stopping the reaction;
(3) Adding 3mol/L hydrochloric acid into the reaction solution to adjust the pH to 5.0, pouring the reaction solution into 1250mL of water, stirring, precipitating a white solid, filtering, drying, dissolving the white solid by using 250mL of methanol under heating, crystallizing at room temperature, filtering, and drying to obtain 51.33g of white solid intermediate product M1, wherein the yield is 95.15% and the purity is 95.11%.
Comparative examples 1 to 1
The other steps are consistent, (2) the reaction solution is cooled to room temperature, the potassium carbonate is removed by filtration, 13g (0.324 mol) of sodium hydroxide is added into the mother solution, the mixture is stirred for 2 hours at room temperature, the reaction is monitored to be complete by thin layer chromatography, and the reaction is stopped; m1 yield 80.05% and purity 95.24%.
Comparative examples 1 to 2
Other steps are consistent, (3) 3mol/L hydrochloric acid is added into the reaction liquid to adjust the pH value to 4.5, the reaction liquid is poured into 1250mL of water, stirred, white solid is separated out, filtered, dried, the white solid is heated and dissolved by 250mL of methanol, crystallized at room temperature, filtered and dried, 38.35g of white solid intermediate product M1 is obtained, and the yield is 71.02% and the purity is 95.40%.
Example 2
The intermediate M2 (N- (2-acetylphenyl) -3, 4-bis (benzyloxy) benzamide) was prepared as follows:
(1) Taking 20g (0.06 mol) of intermediate product M1, adding into 200mL of dichloromethane, adding 0.5mL of N, N-dimethylformamide, dropwise adding 0.3mol of oxalyl chloride at 0 ℃, monitoring the reaction of the raw materials by using a thin layer chromatography, concentrating and drying, and adding 200mL of dichloromethane to obtain a reaction solution 1;
(2) Taking 8.52g (0.063 mol) of 2-aminoacetophenone, adding 200mL of dichloromethane for dissolution, and adding 0.315mol of triethylamine to obtain a reaction liquid 2;
(3) Dropwise adding the reaction liquid 2 into the reaction liquid 1, stirring at room temperature after the dropwise adding, and stopping the reaction after the reaction of the raw materials is monitored by a thin layer chromatography;
(4) And (3) adding 200mL of water into the reaction solution in the step (2), washing the reaction solution, sequentially washing the reaction solution with saturated sodium bicarbonate solution and saturated saline water, drying the reaction solution by anhydrous sodium sulfate, concentrating the reaction solution to dryness, adding 200mL of methanol for heating and dissolving, cooling and crystallizing, filtering and drying the reaction solution to obtain 24.96g of white solid intermediate product M2, wherein the yield is 95.21% and the purity is 93.11%.
Example 2-1
Taking 20g of intermediate product M1, adding the intermediate product M1 into 200mL of dichloromethane, adding 0.5mL of N, N-dimethylformamide, dropwise adding 0.3mol of oxalyl chloride at 5 ℃, monitoring the reaction of the raw materials by using a thin layer chromatography, concentrating and drying, and adding 200mL of dichloromethane to obtain a reaction solution 1; the yield of M2 is 93.97% and the purity is 94.52%.
Comparative example 2-1
Taking 20g of intermediate product M1, adding the intermediate product M1 into 200mL of dichloromethane, adding 0.5mL of N, N-dimethylformamide, dropwise adding 0.3mol of oxalyl chloride at 40 ℃, monitoring the reaction of the raw materials by using a thin layer chromatography, concentrating and drying, and adding 200mL of dichloromethane to obtain a reaction solution 1; the yield of M2 is 84.15% and the purity is 93.03%.
Example 3
The intermediate M3 (2- [3, 4-bis (benzyloxy) phenyl ] quinolin-4-ol) was prepared as follows:
(1) 30g (0.066 mol) of intermediate M2 is taken, 58.15g (0.66 mol) of 1, 4-dioxane and 6.6g (0.165 mol) of sodium hydroxide are added, the temperature is raised to 90 ℃, the reaction is monitored by thin layer chromatography, and the reaction is stopped;
(2) To the reaction solution of step (1) was added 300mL of water, followed by 300mL of ethyl acetate, extraction, separation of the organic phase, drying, and concentration to obtain 26.94g of intermediate M3 as a white solid in a yield of 94.26% and a purity of 94.33% (1 H NMR results are shown in FIG. 2).
Example 3-1
Other steps are consistent, (1) 30g (0.066 mol) of intermediate product M2 is taken, 58.15g (0.66 mol) of 1, 4-dioxane and 6.6g (0.165 mol) of sodium hydroxide are added, the temperature is raised to 80 ℃, and after monitoring the reaction by thin layer chromatography, the reaction is stopped; m3 yield 93.11% and purity 92.21%.
Comparative example 3-1
Other steps are consistent, (1) 30g (0.066 mol) of intermediate product M2 is taken, 58.15g (0.66 mol) of 1, 4-dioxane and 6.6g (0.165 mol) of sodium hydroxide are added, the temperature is raised to 120 ℃, and after monitoring the reaction by thin layer chromatography, the reaction is stopped; m3 yield 89.73% and purity 94.15%.
Comparative example 3-2
Other steps are consistent, (1) 30g (0.066 mol) of intermediate product M2 is taken, 58.15g (0.66 mol) of 1, 4-dioxane and 6.6g (0.165 mol) of sodium hydroxide are added, the temperature is raised to 40 ℃, and after monitoring the reaction by thin layer chromatography, the reaction is stopped; m3 yield 83.86% and purity 92.25%.
Example 4
The intermediate M4 (2- [3, 4-bis (benzyloxy) phenyl ] -4- (cyclopentyloxy) quinoline) was prepared as follows:
(1) 30g (0.07 mol) of intermediate M3 is taken, 300mLN, N-dimethylformamide and 19.35g (0.14 mol) of potassium carbonate are added, the temperature is raised to 80 ℃, the reaction is stirred and stopped after the reaction of the raw materials is monitored by thin layer chromatography;
(2) The reaction solution obtained in the step (1) was added to 400mL of water, and a white solid was precipitated, filtered and dried to obtain 32.42g of a white solid intermediate M4, yield 92.83% and purity 92.43% (1 H NMR result is shown in FIG. 3).
Comparative example 4-1
The only difference from example 4 is that: the potassium carbonate is replaced with an equimolar amount of silver nitrate. The yield was 60.23% and the purity was 92.12%.
Comparative example 4-2
The only difference from example 4 is that: 0.14mol of potassium carbonate was replaced with 0.1mol of potassium carbonate and 0.04mol of tetrabutylammonium bromide. The yield was 82.51% and the purity was 92.87%.
Comparative examples 4 to 3
The only difference from example 4 is that: step (1) is heated to 40 ℃, the yield is 89.26 percent, and the purity is 92.23 percent
Comparative examples 4 to 4
The only difference from example 4 is that: step (1) is heated to 120 ℃, the yield is 82.55 percent, and the purity is 91.97 percent
Example 5
The preparation of the target compound (4- (4- (cyclopentyloxy) quinolin-2-yl) benzene-1, 2-diol) is carried out as follows:
(1) Taking 24g (0.048 mol) of intermediate product M4, adding dichloromethane/methanol (240 mL/48 mL), adding palladium-carbon catalyst (the dosage is 10wt% of intermediate product M4), introducing hydrogen, stirring at normal temperature and normal pressure for replacement, monitoring the reaction completion by thin layer chromatography, and stopping the reaction;
(2) The reaction liquid in the step (1) is filtered and concentrated to obtain a white solid, 240mL of methanol is added, the mixture is heated and dissolved, the temperature is reduced for crystallization, the mixture is filtered and dried, and 15.05g of a white solid target product is obtained, the yield is 97.66%, and the purity is 90.78% (1 H NMR results are shown in figure 4).
Comparative example 5-1
The only difference from example 5 is that the palladium on carbon catalyst was used in an amount of 15% by weight of intermediate M4 in a yield of 87.07% and in a purity of 90.12%.
Comparative example 5-2
The only difference from example 5 is that a palladium on carbon catalyst was used in an amount of 5% by weight of intermediate M4, yield 86.51% and purity 89.36%.
The overall yield of 4- (4- (cyclopentyloxy) quinolin-2-yl) benzene-1, 2-diol prepared by this synthetic route was 77.41%.
Finally, it should be noted that the above description is only for illustrating the technical solution of the present invention, and not for limiting the scope of the present invention, and that the simple modification and equivalent substitution of the technical solution of the present invention can be made by those skilled in the art without departing from the spirit and scope of the technical solution of the present invention.
Claims (10)
1. A preparation method of polyphenol compound is characterized in that the synthetic route is as follows:
Wherein R 1 represents 2-3-OH groups, R 2 represents the same-OCH 2 Ph groups as the-OH substitution positions and the same number in R 1;
the method specifically comprises the following steps:
Step I: adding a raw material compound A, benzyl bromide and inorganic base into an organic solvent A, heating for reaction, cooling to room temperature after the reaction is finished, filtering, adding alkali metal hydroxide, stirring for reaction, and obtaining an intermediate product M1;
Step II: taking an intermediate product M1 for acyl chlorination reaction, removing a solvent after the acyl chlorination reaction is finished, and dissolving the solvent in dichloromethane to obtain a reaction liquid 1; dissolving 2-aminoacetophenone in an organic solvent B, and adding triethylamine to obtain a reaction solution 2; dropwise adding the reaction liquid 2 into the reaction liquid 1, and stirring for reaction to obtain an intermediate product M2;
step III: mixing an intermediate product M2, 1, 4-dioxane and alkali metal hydroxide, and heating to react to obtain an intermediate product M3;
Step IV: adding an intermediate product M3, bromocyclopentane and inorganic base into an organic solvent C, and stirring for reaction to obtain an intermediate product M4;
step V: and adding the intermediate product M4 and the palladium-carbon catalyst into the organic solvent D, and introducing hydrogen for replacement to obtain the polyphenol compound.
2. The preparation method according to claim 1, wherein the compound a is selected from 2, 3-dihydroxybenzoic acid, 2, 4-dihydroxybenzoic acid, 2, 5-dihydroxybenzoic acid, 2, 6-dihydroxybenzoic acid, 3, 4-dihydroxybenzoic acid, 3, 5-dihydroxybenzoic acid, 3,4, 5-trihydroxybenzoic acid or 2,4, 6-trihydroxybenzoic acid.
3. The process according to claim 1, wherein in step i and step iv, the inorganic base is independently selected from potassium carbonate, sodium carbonate and/or sodium hydride; in step I and step III, the alkali metal hydroxide is independently selected from sodium hydroxide, potassium hydroxide and/or lithium hydroxide.
4. The process according to claim 1, wherein in step ii, the acid chlorination reaction proceeds as follows: firstly, adding dichloromethane into the intermediate product M1, then adding N, N-dimethylformamide or N-methyl-N-phenylformamide, and dripping an acyl chloride reagent for reaction.
5. The process according to claim 4, wherein the ratio of the intermediate M1, the acid chloride, the methylene chloride and the N, N-dimethylformamide or N-methyl-N-phenylformamide is 1g:0.5-50mol:1-100mL:0.5-50mL.
6. The process according to claim 4, wherein the acid chloride reaction is carried out at 20 to 30 ℃.
7. The preparation method according to claim 1, wherein the organic solvent a is selected from N, N-dimethylformamide or N-methyl-N-phenylformamide; the organic solvent B is selected from acetonitrile, dichloromethane, ethylene glycol dimethyl ether, methanol or acetone; the organic solvent C is selected from N, N-dimethylformamide or N-methyl-N-phenylformamide; the organic solvent D is at least one selected from acetonitrile, dichloromethane, ethylene glycol dimethyl ether and methanol.
8. The preparation method according to claim 1, wherein in the step I, the dosage ratio of the compound A, benzyl bromide and inorganic base is 1mol:0.35-35mol:0.5-50mol; the molar ratio of the compound A to the alkali metal hydroxide is 1:0.2-20; in the step II, the dosage mole ratio of the intermediate product M1, triethylamine and 2-amino acetophenone is 1mol:0.5-50mol:0.105-10.5mol; in step III, the ratio of the amount of the intermediate M2, 1, 4-dioxane and the alkali metal hydroxide is 1mol:1-100mL:0.25-25mol; in the step IV, the dosage ratio of the intermediate product M3, the bromocyclopentane to the inorganic base is 1mol:0.1-10mol:0.2-20mol.
9. The preparation method according to claim 1, wherein in the step v, the mass ratio of Pd to C in the palladium-carbon catalyst is 0.03 to 0.3:1, a step of; the dosage of the palladium-carbon catalyst is 8-12wt% of the intermediate product M4; preferably, the mass ratio of Pd to C in the palladium-carbon catalyst is 0.1:1, a step of; the palladium on carbon catalyst was used in an amount of 10wt% of the intermediate product M4.
10. The method of claim 1, wherein in step i, the heating reaction temperature is 0-80 ℃; in the step II, the stirring reaction is carried out at 0-20 ℃; in the step III, the temperature is 50-100 ℃; in the step IV, the stirring reaction temperature is 50-100 ℃.
Publications (1)
Publication Number | Publication Date |
---|---|
CN118290332A true CN118290332A (en) | 2024-07-05 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109503572B (en) | Method for synthesizing indole quinoline compounds | |
CN109970705B (en) | Method for preparing brexpiprazole intermediate and brexpiprazole by using cheap metal copper | |
CN112266392A (en) | Process for preparing CENICRIVIROC and related analogs | |
KR101000362B1 (en) | A Novel Synthetic Method of Itopride and derivatives | |
CN110305018B (en) | Preparation method of 3-bromo-2-fluoronitrobenzene | |
JPH0674243B2 (en) | Optically active atenolol salt with high optical purity and process for producing atenolol | |
CN116514704B (en) | Rafenacin intermediate and preparation method thereof | |
CN112409201A (en) | Preparation method of 2-hydroxy-5- [2- (4- (trifluoromethylphenyl) ethylamino) ] benzoic acid | |
CN118290332A (en) | Preparation method of polyphenol compound | |
CN111100042B (en) | Preparation method of 2-methoxy-5-sulfonamide benzoic acid | |
CN114716331A (en) | Preparation method of dopamine hydrochloride | |
CN110845410B (en) | Method for preparing 6, 7-dimethoxy-3, 4-dihydroisoquinoline hydrochloride by one-pot method | |
CN108409561B (en) | Preparation method of 5-aminolevulinic acid hydrochloride and intermediate | |
CN103333103B (en) | Method for preparing flupirtine maleate by one-pot method | |
CN109651234B (en) | Synthesis method of donepezil hydrochloride | |
CN112250586A (en) | Preparation method of terbutaline sulfate and B crystal form thereof | |
CN112209841B (en) | Synthesis method of terbutaline and application of terbutaline in preparation of terbutaline sulfate | |
CN113004230A (en) | Furosemide and purification method thereof | |
CN108203396B (en) | Synthesis of enkephalinase inhibitor | |
CN105481831B (en) | A kind of method for preparing dabigatran etexilate intermediate | |
CN114790135B (en) | Preparation method of benzoyl formic acid | |
JP7453365B2 (en) | High purity N-(5-methoxy-2-phenoxyphenyl)methanesulfonamide and its production method | |
CN116874360B (en) | Synthesis method of buparvaquone | |
CN109824537B (en) | Preparation method of N- (3-acetyl-2-hydroxyphenyl) acetamide | |
CN113429333B (en) | Synthesis method of gatifloxacin intermediate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication |